Gilead Raday, COO, RedHill Biopharma discusses development of the next generation of effective therapies for gastrointestinal disorders and cancer that affect millions of people worldwide.  This includes treatment for H. pylori infections which can cause ulcers and gastric cancer, the first-ever therapy for Crohn's disease that targets the hypothesized bacterial cause of the disorder, and additional therapies for IBS-D and gastroenteritis. @RedHillBio RedHill Biopharma